ABCG2 and cancer: However, compounds 2 and 3 were generally less active towards resistant cancer cells, with 3 showing collateral sensitivity towards resistant breast adenocarcinoma MDA-MB-231/BCRP cells (D.R.: <0.70 compared to its sensitive subline MDA-MB-231) [37].